US20070031482A1 - PDT treatment method for cellulites and cosmetic use - Google Patents

PDT treatment method for cellulites and cosmetic use Download PDF

Info

Publication number
US20070031482A1
US20070031482A1 US11/489,873 US48987306A US2007031482A1 US 20070031482 A1 US20070031482 A1 US 20070031482A1 US 48987306 A US48987306 A US 48987306A US 2007031482 A1 US2007031482 A1 US 2007031482A1
Authority
US
United States
Prior art keywords
photosensitizer
cellulite
area
treatment
method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/489,873
Inventor
Danilo Castro
Wolfgang Neuberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolitec Pharma Marketing Ltd
CeramOptec Industries Inc
Original Assignee
CeramOptec Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US70479705P priority Critical
Application filed by CeramOptec Industries Inc filed Critical CeramOptec Industries Inc
Priority to US11/489,873 priority patent/US20070031482A1/en
Assigned to CERAMOPTEC INDUSTRIES, INC. reassignment CERAMOPTEC INDUSTRIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CASTRO, DANILO, NEWBERGER, WOLFGANG
Assigned to CERAMOPTEC INDUSTRIES, INC. reassignment CERAMOPTEC INDUSTRIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CASTRO, DANILO, NEUBERGER, WOLFGANG
Publication of US20070031482A1 publication Critical patent/US20070031482A1/en
Assigned to BIOLITEC PHARMA MARKETING LTD. reassignment BIOLITEC PHARMA MARKETING LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOLITEC, INC.
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/06Preparations for care of the skin for countering cellulitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/81Preparation or application process involves irradiation

Abstract

A photosensitizer mixture and a method of treating cellulites by means of a percutaneous application of the mixture into the area of cellulite buildup followed by light illumination are presented. The photosensitizer can be combined with one or more cellular products including adipose cells and/or collagen that have been previously removed by liposuction. This mixture can also include other compounds such as Lipofundin MCT 10% to improve the photosensitizer's diffusion or to dilute it Varying concentrations are used depending on the area of treatment as well as the stage of the cellulites and whether the cellulites present a depressed area in the skin or an elevated area. The cosmetic treatment method substantially reduces or removes localized lipodystrophies and/or flaccidity and/or cellulite by localized laser, LED or other light irradiation of the area of treatment having a photosensitizer applied therein. The light energy is applied to destroy the “fat” cells by a combination of chemical reactions, primarily, and temperature wherein the cell walls break releasing the cell fluid. The light radiation is generally applied through devices to guide the radiation to the area of treatment. One or more light sources such as laser diodes or LEDs may be coupled into one or more optical fibers to increase the area of coverage as well as increase the amount of radiation in that area of coverage. Optical fibers can be introduced percutaneously or possibly interstitially into the area of treatment. Cell fluid in the area of treatment is removed by a combination of techniques. Quick and lasting cosmetic changes in areas having prior untreatable cellulite fat tissues are achieved while minimizing trauma.

Description

    DOMESTIC PRIORITY UNDER 35 USC 119(e)
  • This application claims the benefit of U.S. Provisional Application Ser. No. 60/704,797, filed Aug. 2, 2005, which is incorporated by reference herein.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to the field of cosmetic treatment and, in particular, relates to a photodynamic therapy treatment to remove cellulite tissue and also excess adipose cells in areas of the body prone to buildup of such tissues.
  • 2. Invention Disclosure Statement
  • It is a well known fact that modern society has created an abundance of readily available foods, i.e., “fast foods,” and also has created an environment where entertainment has fostered a sedentary life style of, for example, watching television, playing video games and talking on the phone while eating high caloric snack foods. This has allowed people to gain excessive weight by an increase in adipose tissue, fat cells. Certain heredity conditions further have also created areas of excessive fat cells that are difficult to remove in that they are in areas that are not affected or minimally affected by diet and exercise. In an area where fat cells have excessively accumulated, normally in the buttocks, hips, and thighs, especially in women, the collagen fibers are deformed which allows pockets of fat cells to build up and deform the skin surface into producing bubbles or ripples, also called cellulite.
  • “Edematous-fibrosclerotic panniculopathy” is a medical term used to describe cellulite. Cellulite affects 80-90% of women in their post-pubertal period. Cellulites are found commonly on the hips, thighs, and buttocks giving a dimpled appearance in those areas of the body. It is not a disorder but an issue of cosmetic concern to the individual. Cellulite is most often seen in women than in men due to the structural differences of their adipose tissue. Cellulite is not related to obesity or overweight, since it can occur even in normal and thin women.
  • Cellulite is different from fat cell layer in the body. Most fatty deposit in the individual depends on his/her weight, life style and genetic makeup. Fat layer in the body had important function of insulation, protecting vital organs etc. while cellulite is largely due to structural conformation below the skin which appears as lumpy pockets of trapped fat giving uneven dimpling or orange peel skin.
  • Cellulite develops in the hypodermis or subcutaneous fat layer, where fat lobes are organized into chambers by surrounding strands of connective tissue. Below this layer is scarpus fascia in which fat cells get larger when weight is gained. This layer is divided into chambers by connective tissue, which attaches the top layer of the skin to the lower layers of muscle. When these connective tissues become weak, the scarpus fascia bulges upward, causing the characteristic uneven, dimpled appearance in the skin.
  • Most procedures are ineffective in removing cellulite except for a long term dieting and exercise. The development of cellulite is genetically driven and is considered a normal condition and is thus difficult to remove.
  • Excessive fat depositions or “lipodystrophies” are produced by a disproportionate increase in the deeper section of the subcutaneous cellular tissues of fat cells.
  • Lipodystrophies are produced because the adiposities have a hereditary genetic code which makes them evolve in a specific way. Each adipocite cell has Beta 1 (lipogenetic) and Alfa 2 (lipolitic) receptors in its membrane. When there are more Beta 1 receptors on a particular area, then a localized obesity or lipodystrophy is produced. Because of the excessive Beta receptors in certain families, these families have a tendency for enlarged legs, breasts, waists, etc. On these patients treatment with low caloric diets exclusively is normally not successful which leads to abandonment of the treatment and recovering whatever localized fat was removed and returning to the same unhealthful practices.
  • The only effective way to treat cellulite is to directly act on the genetically altered fat tissues and similar tissues in the area of treatment.
  • Historically, different methods have been developed to treat this problem and billions of dollars are being spent annually by people to remove or reduce fat tissue in these areas of the body. By the late 70's liposuction started to be used followed by liposculpture in the late 80's being an improved liposuction performed under local anesthesia using traumatic trocars to remove fluids. Later ultrasonic liposculpture was developed by mid 90's and there are some reports on “laser liposuction” (using an external laser source) but laser assisted liposuction has not been clearly proved to be effective so far.
  • Among the patents covering the state of the light are the following.
  • U.S. Pat. No. 6,206,873 by Paolini, et al., titled, “Device and Method for Eliminating Adipose Layers by Means of Laser Energy,” discloses a hollow needle with an optical fiber in the center. The fat tissue, adipose cells, is liquidized when the cell walls are broken. The fluid is removed by suction through the needle. The laser is used to simply thermally degrade the cell walls. Laser wavelength range is noted as from 0.75 to 2.5 microns but a preferred wavelength of 1.06 is called out. A rounded optical fiber end is shown in FIG. 3 beyond the needle end. Paolini et al. use a Nd:YAG type of laser and note a wavelength range above. Paolini et al. further note that the liquid produced may be removed from the body by normal absorption.
  • While in U.S. Pat. No. 6,605,080 Altshuler et al. disclose the removal of lipid rich tissue using external laser, a YAG source as well as other lasers whose output energy are in a wavelength range of 880 to 935 nm, 1150 to 1230 nm or 2280 to 2360 nm. It is noted that the radiation in the lower bands, specifically, 900 to 930, and 1150 to 1230, are preferred in the treatment of fat tissue. Specifically, wavelength regions near water/OH absorptions are identified as not preferred. Also they recommend the use of a cooling system.
  • U.S. Pat. No. 6,743,215 by Bernakei, titled, “Method and Apparatus for Skin Absorption Enhancement and Cellulite Reduction” discloses a process including the application of a compound upon an abraded skin surface followed by electrical and mechanical to remove cellulite.
  • Publication WO 99/48474 by A. Casale, entitled, “Pharmaceutical or Cosmetic Compositions Containing Photosensitizer Substances,” discloses a photosensitizer formulation of liposomes with the PS activated by a light of the wavelength between 700 and 900 nm. While the invention is basically about an effective formulation of photosensitizer agent for use in pharmaceutics and cosmetic applications, photosensitizers or precursors with activation bands away from.
  • Most of the prior art methods mentioned above are useful for fat reduction (over weight or obesity), while cellulite is a different condition related to fat cells which cannot be addressed effectively using the above methods. Presently there is no truly effective treatment for cellulite.
  • There is thus a need for treatment techniques that minimizes surface distortion, post operative complications, and removes or reduces cellulite problem from selected areas. The present invention satisfies that need.
  • OBJECTIVES AND BRIEF SUMMARY OF THE INVENTION
  • It is an objective of the present invention to provide a method of cosmetic treatment using laser, LED or other (e.g. a filtered lamp) radiation in conjunction with a photo-drug for the destruction of cellulite tissue in the area of treatment.
  • It is another objective of the present invention to provide a method of cosmetic treatment using radiation and a photo-drug that directly affects the sub-dermal fatty tissues.
  • It is yet another objective of the present invention to provide a method of cosmetic treatment using PhotoDynamic Therapy (PDT) to directly affect adiposites causing emulsification of the fatty tissue and then elimination by absorption, removal by the lymphatic system and by drainage.
  • It is still another objective of the present invention to provide a method of cosmetic treatment using PDT to directly affect the fatty tissues without destruction of the structural tissues.
  • It is a further objective of the present invention to provide a photosensitizer mixture to be used in a method of cosmetic treatment using PDT to reduce cellulites.
  • Briefly stated, the present invention provides a photosensitizer mixture and a method of treating cellulites by means of a percutaneous application of the mixture into the area of cellulite buildup followed by light illumination is presented. The photosensitizer can be combined with one or more cellular products including adipose cells and/or collagen or hyaluronic acid or compounds that have been previously removed by liposuction. This mixture can also include other compounds such as Lipofundin MCT 10% to improve the photosensitizer's diffusion or to dilute it Varying concentrations are used depending on the area of treatment as well as the stage of the cellulites and whether the cellulites present a depressed area in the skin or an elevated area. The cosmetic treatment method substantially reduces or removes localized lipodystrophies and/or flaccidity and/or cellulite by localized laser, LED or other light irradiation of the area of treatment having a photosensitizer applied therein. The light energy is applied to destroy the “fat” cells by a combination of chemical reactions, primarily, and temperature wherein the cell walls break releasing the cell fluid. The light radiation is generally applied through devices to guide the radiation to the area of treatment. One or more light sources such as laser diodes or LEDs may be coupled into one or more optical fibers to increase the area of coverage as well as increase the amount of radiation in that area of coverage. Optical fibers can be introduced percutaneously or possibly interstitially into the area of treatment. Cell fluid in the area of treatment is removed by a combination of techniques. Quick and lasting cosmetic changes in areas having prior untreatable cellulite fat tissues are achieved while minimizing trauma.
  • The above, and other objects, features and advantages of the present invention will become apparent from the following description read in conjunction with the accompanying drawings.
  • BRIEF DESCRIPTION OF FIGURES
  • FIGS. 1A and 1B illustrate the before and after treatment of a hip area within days after treatment of a first patient by the method/composition of the present invention;
  • FIGS. 2A and 2B illustrate the before and after treatment of a lower buttock area within days after treatment of said first patient by the method/composition of the present invention;
  • FIGS. 3A and 3B illustrate the before and after treatment of a thigh area within days after treatment of said first patient by the present invention;
  • FIGS. 4A, and 4B illustrate a second patient having cellulites in typical areas of the body;
  • FIGS. 5A and 5B illustrate the second patient, after having treatment by the present invention, showing the absence of cellulites in these same typical areas.
  • FIG. 6 illustrate a third patient before treatment and then 1 month and 6 months after treatment by the method and composition of the present invention;
  • FIG. 7 illustrates the process of Temoporfin interacting with cells.
  • FIG. 8 illustrates the chemical makeup of Temoporfin.
  • FIGS. 9A and 9B illustrate appropriate marking of sectors having cellulite thereon.
  • FIG. 10 to 16 presents before and after pictures, of varying days, of 8 female patients, ranging in age from 23 to 56 years initially having Stage II, III or IV cellulites which pictorially demonstrates the success of the present invention in reducing the stage of cellulites in each patient;
  • DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
  • Many women suffer, have suffered or are going to be at some time afflicted with cellulites in their life. It is an esthetic pathology that only has pathological general connotations.
  • It is a problem that belongs to mostly women, in general, and normally women older than 20 years.
  • The appearance of cellulites is a psychologically depressing event to many women because it appears in body areas that are exposed when wearing bathing suits, for example. The skin has a bubbly appearance with depressions and hills. Millions of dollars are spent by women seeking a cure each year for numerous advertised remedies by the cosmetology industry. Many of these remedies do not provide any long term solutions but only temporary relief by the elimination of excess water from cellular tissues.
  • There is not an adequate definitive solution, just medical and cosmetologic treatments that generally do not achieve the patient's complete satisfaction.
  • The goals of the present invention in regards to the treatment of cellulites is to: (1) provide a method of esthetic alterations of the skin for improving its visual aspect; (2) provide a process for homeostasis of the cells that are altered in the treatment of cellulites; and (3) increase of the web of collagen for optimizing the results of the adipose graft when treating cellulites.
  • In the present invention, suitable photosensitizers porphyrins and their derivatives, including temoporfin, chlorins, bacteriopheophorbide, bacteriochlorins etc are used. The selected photosensitizer can be administered using suitable delivery systems like liposomes, prodrug etc for efficient drug delivery to selected target cell. As commonly used throughout this specification and claims ‘photosensitizer’ is used to include precursors of photosensitizers, which naturally become photosensitizers after introduction into a patient as the precursor.
  • The series of photographs, FIG. 1 to 6, present dramatic evidence of the success of the present invention in substantially reducing the effects and appearance of cellulites in three patients after only 1 or several treatments and only a few days after the treatments.
  • When the photosensitizer Temoporfin is activated with light from a diode laser, e.g., 652 nm wavelength, this produces an intracellular oxidation that is believed to act to modify the cell membrane's properties, the cytoplasm, ribosomas, Golgi's appliance, and nucleus, eventually triggering a series of events that result with the cell apostosis.
  • The cell when exposed to the effects of Temoporfin or other photosensitizer begins a series of morphologic changes. The plasma membrane alters and the characteristic blebbing appears. The cell volume decreases considerably and the cytoplasm condenses. The nucleus becomes smaller and chromatin become denser and eventually collapses splitting into several spheres of material.
  • At the end of apostosis, the cell is ingested by phagocytosis or by nearby cells avoiding the inflammatory response typical during normal cell necrosis. Even though the cell disappears, there is an increase of the collagen web. This improves the support of collagen, realignment of the collagen fibers and elastin, decreases the gelatinous consistency of the fundamental inter-cell substance, improves oxygenation and cell nutrition, and decreases toxic metabolites' retention and the edema.
  • Temoporfin is a very efficient generator of active oxygen which does not require a large dose of the drug nor a long exposure to light.
  • FIG. 7 illustrates the process of Temoporfin's interaction upon activation.
  • The intracellular oxidation is responsible for the alterations of the membrane's surface and the nuclear, the mitocondrias, Golgi's appliance, the net endoplasmatic and the ribosomas resulting in the death of the cells or cell apoptosis.
  • Temoporfin in the past has been used in the treatment of some head and neck cancers.
  • Temoporfin is totally innocuous and inactive in the dark and is activated with low intensities of light and it turns into a powerful isolated-oxygen generator.
  • EXAMPLE 1
  • A patient having cellulites is treated with Temoporfin in several sessions.
  • The variables in this treatment program are as follows:
    • 1.—A determination of the grade of cellulites in the patient.
    • 2.—A determination of the dose and concentration of Temoporfin and to confirm that it produces an improvement on the cellulites, and to further insure that it is possible to apply it directly by Mesotherapy without the need of systemic introduction.
    • 3.—A determination as to the potency of Temoporfin based on the time of application to the time of laser application; and
    • 4.—A determination as to accompanying treatments.
  • The dilutions used for treatment are presented in the following Table 1:
    TABLE 1
    CONCEN-
    PURE PHYSIOLOGICAL TRATION
    PRODUCT TEMOPORFIN SERUM mg/ml
    5 gr. 7.5 mg  5 ml 1.5 mg/ml
    5 gr. 7.5 mg 25 ml 0.3 mg/ml
    5 gr. 7.5 mg 37.5 ml   0.2 mg/ml
    5 gr 7.5 mg 50 ml 0.15 mg/ml 
    5 gr 7.5 mg 75 ml 0.1 mg/ml
  • To treat cellulites a concentration of 0.005 mg/ml is applied directly by Mesotherapy. This concentration results from the study of optimal concentrations for the use of m-THPC on the treatment of tumors: 0.1 to 0.3 micrograms per gram of tumor tissue. The aesthetic doses are 10 times lower as the objective is to develop a collagen matrix and not destroy a tumor. Therefore, the aesthetic doses range from 5 to 15 μg/50 gr of cellulites tissues.
  • To apply Mesotherapy on 50 gr of tissue, 2 cc of solution is applied (area of 100 cm2 with a diffusion of 0.5 cm depth).
  • Finally, 2 cc of Mesotherapy solution must contain 0.005 to 0.015 mg of m-THPC so its concentration must be as follows: Concentration of M-THPC for Mesotherapy on cellulites: 0.005 mg/ml to 0.01 mg/ml.
  • General Procedure:
  • In order to determine the stage as well as the location of the cellulites in the patient, CONTACT THERMOGRAPHY may be used.
  • High Resolution Contact Thermography is ideal to accomplish classification of the grade of cellulites and patient tracking during treatment since small variations are evidenced during treatment.
  • This process measures the superficial temperature of the skin surface when placed in contact therewith by means of a plate of capsulated liquid crystals. The color of the crystals is an indication of the temperature of the underlying skin. Several plates are available having different temperature ranges appropriate for skin application. Two of these plates are shown below:
    Figure US20070031482A1-20070208-P00001
  • The brown colors mark hypothermic zones with little circulation and the blue colors indicate hypothermic zones with increased circulation. The temperatures are registered on the skin and provide 3 or 4 grades of temperatures of the hypodermis. The homogeneous imagery indicates the condition of the cellulites and provides exactness of diagnosis, topography and the cellulites stage. The following are examples of imagery from cellulites areas as well as the stages associated with that cellulites:
    Figure US20070031482A1-20070208-P00002
  • This is a uniform, unstained color image that is obtained at sectors with absence of cellulites. A reference termography may be done on the arm or on the forearm zones that in general do not present cellulites.
  • Evolutionary grades or cellulites stages used in the treatment of patients:
  • The following conditions are indicative of Stages I and II: Slowing down of the venous and lymphatic circulation; with the dilatation of the little veins of the deep cape of the dermis. Interstitial edema at zones surround the adipose cells. The exudation increases rapidly for the serum from the capillaries of the subcutaneous tissue. The zone with edema compresses the conjunctive fibers as well as the nervous elements, and it can manifest itself with pain by touch and at times spontaneous. There may be alterations of sensibility and formation of stretch marks.
  • There is histology of hyperplatia and hypertrophy of the reticular fibers that surround the adipose cells and the capillaries. These phases are reversible.
  • Thermography in these stages presents hyperthermic big and diffuse borders, surrounded stains evidence hypodermic diffuse zones and the image translates the alteration and instability of the microcirculation of the zone.
    Figure US20070031482A1-20070208-P00003
  • In Stage III, there is fibrous proliferation. The fibers swell up and there is a decrease of collagen, an increase in the fibrin and loss of the individual characteristics of little fibers that mask a named fibrinoide type. Collagen is deconstructed and degenerated, forming irregular, amorphous blocks, losing its structure and provoking confinement of the full adipositos of tri-glycerides. The clinical and visual aspect is termed the “orange skin.” There is slowing down of cell vascular interchanges thus forming micronodules. The reversibility of the effect becomes more difficult in this phase.
  • Thermography evidence: The image is a multi-colored image where the predominate colors are celestial green and pink. Leopard's aspect of the skin localizes the irregularities of temperature in the skin for effect of the micronodules. The very cold zones that the black announces begin to appear as “Black Holes” which characterize stage IV cellulite.
  • SKIN OF LEOPARD or MICRONODULES or STAGE III (III)
    Figure US20070031482A1-20070208-P00004
  • Stage IV: The fibrosis increases and compresses veins and nerves producing an alteration of the elements of the conjunctive tissue. The adipose tissue is divided into compartments like tablets with large hypothermic blocks because of its low sanguine circulation. The adipocytes are normal, but they are compressed. Several contiguous intervening micronodules fuse as one capsule making a macronodule that is palpable.
  • Clinically the skin presents a padded appearance with presence of painful isolated macronodules or in conglomerate forming hard plates evidences itself. In this stage there is flabbiness.
  • Thermographically, the image presents one of Black Holes with extensive hypodermic zones that indicate that macronodules are presence.
  • In this EXAMPLE, the patient is administered the Temoporfin solution as follows: In all sequences, the treatment consists 1 session only per area to be treated, and, if necessary, it is repeated in 30 days. In general, it was observed that only 1 session followed by appropriate physiotherapy, a complementary session (like ultrasound, lymph-drainage, isotonic and isometric electro-stimulation), was usually sufficient in more than 80% of the patients. If it was necessary to repeat it, an evaluation is done after 30 days.
  • Other treatments included in this process might include the following, as examples:
    • Ultrasound; Lymphodrain and presotherapy; Thermotherapy; and Isometric Electrotonotherapy.
  • Table 2 presents further information as to the stage of cellulite, concentration of mTHPC (Temoporfin), dose, surface area being treated; strength, power level and time of laser radiation application.
    TABLE 2
    The PDT's application TEMOPORFIN will follow the following parameters
    CELLULITIS M - THPC DOSE SURFACE LATENCY Watts TIME PDT
    I HARROW I II 0.1 mg/ml 10 cc 600 cm2 (20 × 30) 30′ 2 W 2′ each 100 cm2
    I HARROW III 0.2 mg/ml 10 cc 600 cm2 (20 × 30) 30′ 2 W 2′ each 100 cm2
    I HARROW IV 0.2 mg/ml 10 cc 400 cm2 (20 × 20) 30′ 2.5 W   3′ each 100 cm2
  • These parameters are adjusted according to the patient's condition.
  • The following is a listing of the sequence of events in each session:
  • Accomplish a mapping with sectorial (See FIG. 9) thermographic images and the recording of this information as to each patient for reference during treatment;
  • Identify zones on the patient's body where there are areas of treatment;
  • Disinfect skin with alcohol;
  • Apply the Temoporfin solution in accordance with the treatment plan established;
  • Apply ultrasound at the rate of 1 minute for each 100 cm2 of surface which further helps distribute the product within the cellulite tissue;
  • Wait for 30 minutes;
  • Apply the laser radiation from about 6.25 to 2.5 cm from the dermic surface, with a spot of 3 cm, with a continuous mode, with a potency of 2 watts, for 2 or 3 minutes on each 100 cm2 depending on grade and applied dose.
  • Apply a cold gel covered by plastic film to the areas of treatment;
  • Apply the cold gel film for 2 hours;
  • Allow the patient to remove the cold gel with a natural sponge applied in circles after the treatment sessions.
  • The results of the treatment should be followed by thermography noting cold zones, micro-nodules and black holes. The patient's body should be divided into sectors with the stage level noted for each. This is beneficial for followup treatments and consultation. Pictures of a body are included noting the different sector numbers.
  • Sector 1: Gluteus
  • Sector 2: Posterior of thigh
  • Sectors 3 to the 8: Anterior of thigh
  • Because of the low dose concentration of Temoporfin, the cost should be low so that it will be affordable.
  • Further, Lipofundin MCT 10% may be applied in the tissue with there is cellulites to improvement the Temoporfin's diffusion. Further, Lipofundin may be used to dilute the Temoporfin.
  • EXAMPLE 2
  • Temoporfin is a photosensitizer from a group that have affinity to phospholipids and cell membranes but are not soluble in triglycerides.
  • The appearance of cellulites, in the more severe stages, is a bubbling affect having depressed areas and hill like areas. These areas may require special treatment as follows:
    • 1) For filling depressed areas:
  • a. the diluted Temoporfin (formulated in a liposome) is mixed 0.3 mg per ml;
  • b. fat from liposuction is washed and mixed with the diluted temoporfin at a ratio 5 parts to 1 part;
  • c. an 18G needle is used to give the shot of this mixture in the depressed area;
  • d. 30 minutes wait after shot;
  • e. PDT treatment; and
  • f. the treated area is washed.
    • 2) For elevated zones or hills
  • a. a mesotherapy with Temoporfin (formulated in a liposome) having 0.3 mg per ml was diluted.
  • b. inject this mixture into the area of treatment;
  • c. wait 30 minutes; and
  • d. PDT treatment.
  • In general the procedure is as follows: 1. analysis and marking off of areas to be treated; 2. adding fluid to areas, after local anesthetic applied; 3. lasing of tissue within each area of treatment; 4. squeeze and suction of melted fat; and 5. application of ointments, etc., after treatments.
  • EXAMPLE 3
  • Steps for Patient Assessment and Treatment for Localized Cellulite:
    • 1) Diagnostic: Clinical evaluation with anthropometric measurements, weight and pictures complemented by the use of Thermograph charts to confirm the clinical assessment of the cellulites stage (I, II, III and IV)
    • 2) Treatment:
  • a. Temoporfin (formulated in a liposome) Mesotherapy deep injection:
  • 1. 2 cc/100 cm2 of area to be treated @ 0.05 mg/ml temoporfin dilution (Stage IV) only 1 injection used; and
  • 2. 2 cc/100 cm2 of area to be rated @0.025 mg/ml temoporfin dilution (Stage II and III) only 1 injection;
  • For example, on a buttock area of treatment, 6 or 8 cc of solution is used (@ 0.05 or 0.025 depending on the stage of the condition) For serious conditions, liposuction is used to obtain some of the patient's own fat which is cleaned and injected into the depressed areas;
  • b. Lymph-drainage/soft massage: This helps to distribute the drug within the area of treatment;
  • c. Wait 30 minutes;
  • d. Laser Illumination: area is divided into spots to cover the whole area and a fluence of 0.8 J/cm2 is used on stage II & III (with 0.5 W and time according to the area) or 1 J/cm2 on stage IV (with 0.75 W).
    • 3) Post-Immediate:
  • a. Gel application; and
  • b. Light compression stockings.
    • 4) Post @ 48 hrs: complementary sessions could be applied like: lymph-drainage, press therapy, ultrasound, gels, etc.
    • 5) Follow-up: Assessment of results.
  • FIGS. 10 through 16 present examples of patients before and after treatment.
  • EXAMPLE 4
  • LED Based PDT for Cellulite Reduction
  • Before starting the treatment, patient clinical history is studied and physical examination is performed. The cellulite is staged by clinical impression and by thermography.
  • Liposomal formulation of temoporfin diluted in 5% gluocuse solution is used. Diluted liposomal formulated temoporfin (1 part) is mixed with lipofundin (9 part) which helps better drug diffusion into the cellulite.
  • Pistol like device with trigger is used for injecting the drug into the treatment site. Single shot using the device delivers 12 μl of liposomal formulated temoporfin; each injection site receives two such shots to a depth of 0.5 cm. Each injection site is separated from each other by 0.5 cm approximately. Dose of the drug can be increased based on the cellulite stage which needs to be treated.
  • Illumination is performed using LED arrays (area of the array is 4*4 cm) with wavelength 652 nm, power density 180 mW/cm2.
  • Treatment schedule: 4 LED treatments are performed in the patient. The first starts 48 h after injection of the liposomal formulated temoporfin. The second, third and fourth are performed on 7, 14 and 21 days after injection respectively.
  • Patient is examined at the end of 21 days and later follows ups showed good improvement with better skin texture resulting in smoother skin.
  • For the sake of this invention and particularly for the claims, some precursors of photosensitizers become photosensitizers by the natural activity of the animal injected with them. These are considered, therefore to be included within the general word, “photosensitizers” used in the claims and general specification, as was noted earlier.
  • Having described preferred embodiments of the invention with reference to the accompanying drawing, it is to be understood that the invention is not limited to the precise embodiments, and that various changes and modifications may be effected therein by skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

Claims (20)

1. A method of reducing unwanted cellulite in selective areas of an organism comprising the steps of:
a. identifying said selective areas to be treated;
b. administering at least one photosensitizer to said organism;
c. allowing a sufficient time for said photosensitizer to accumulate in cellulite of the selective area of treatment; and
d. selectively activating by light said photosensitizer in said selective areas to reduce/eliminate cellulite.
2. The method of reducing unwanted cellulite according to claim 1, wherein said photosensitizer has an affinity to phospholipids and cell membranes but is substantially not soluble in triglycerides.
3. The method of reducing unwanted cellulite according to claim 1 further including before step b, a step of mixing said photosensitizer into a mixture of cellular tissues from said organism.
4. The method of reducing unwanted cellulite according to claim 3 wherein said cellular tissues are selected from the group consisting of adipose cells, and collagen.
5. The method of reducing unwanted cellulite according to claim 4 wherein a treatment fluid comprising said photosensitizer and said cellular tissues mixed in a ratio of about 1 part to 5 parts by volume.
6. The method of reducing unwanted cellulite according to claim 4 wherein a volume of said treatment fluid administered to said selective area is adjusted according to whether said cellulite is in a depressed area of the skin or an elevated area on the skin.
7. The method of reducing unwanted cellulite according to claim 1 wherein said administering step is by local application to the areas to be treated.
8. The method of reducing unwanted cellulite according to claim 1 wherein said selectively activating is by means of electromagnetic radiation, wherein said electromagnetic radiation includes a wavelength matching at least one peak within said photosensitizer's absorption spectrum, and wherein said electromagnetic radiation is emitted by a light source selected from the group consisting of diode lasers, LEDs, and one or more lamps with filters.
9. The method of reducing unwanted cellulite according to claim 8 wherein said radiation is applied by means of at least one optical fiber.
10. The method of reducing unwanted cellulite according to claim 9 wherein said optical fiber has an output tip having a diffusing device thereon.
11. The method of reducing unwanted cellulite according to claim 1 wherein said cellulite is adipose tissue accumulated in pockets under the skin of said organism forming depressed and elevated areas.
12. The method of reducing unwanted cellulite according to claim 11 wherein adipose tissue is white adipose tissue.
13. The method of reducing unwanted cellulite according to claim 1 wherein said cellulite are adipocytes.
14. The method of reducing unwanted cellulite according to claim 1 wherein said identifying step comprises the use of thermography to determine the stage of cellulites.
15. A photosensitizer mixture for treating cellulite tissue comprising:
a hydrophobic photosensitizer; and
a carrier.
16. The photosensitizer mixture according to claim 15, wherein said photosensitizer has an affinity to phospholipids and cell membranes but is substantially not soluble in triglycerides.
17. The photosensitizer mixture according to claim 16, wherein said photosensitizer is Temoporfin (mTHPC).
18. The photosensitizer mixture according to claim 17 wherein in said Temoporfin is present within liposomes.
19. The photosensitizer mixture according to claim 15 further comprising a material selected from the group consisting of Lipofundin, hyaluronic acid, and collagen/adipose previously removed by liposuction.
20. The photosensitizer mixture according to claim 19, wherein said material and said photosensitizer are present in a ratio of about 5 parts to 1 part by volume, respectively.
US11/489,873 2005-08-02 2006-07-20 PDT treatment method for cellulites and cosmetic use Abandoned US20070031482A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US70479705P true 2005-08-02 2005-08-02
US11/489,873 US20070031482A1 (en) 2005-08-02 2006-07-20 PDT treatment method for cellulites and cosmetic use

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US11/489,873 US20070031482A1 (en) 2005-08-02 2006-07-20 PDT treatment method for cellulites and cosmetic use
BRPI0614453 BRPI0614453A2 (en) 2005-08-02 2006-07-27 cululite undesired reduction method in selective areas of a body and photosensitizer mixture
CN 200680028493 CN101568344B (en) 2005-08-02 2006-07-27 Pdt treatment method for cellulites and cosmetic use
CA 2616461 CA2616461C (en) 2005-08-02 2006-07-27 Pdt treatment method for cellulites and cosmetic use
ES06813236.4T ES2659917T3 (en) 2005-08-02 2006-07-27 Method of treatment of photodynamic therapy (PDT) for cellulite and cosmetic use
AU2006275721A AU2006275721B2 (en) 2005-08-02 2006-07-27 PDT treatment method for cellulites and cosmetic use
KR1020087005284A KR101330120B1 (en) 2005-08-02 2006-07-27 Pdt treatment method for cellulites and cosmetic use
EP06813236.4A EP1928466B1 (en) 2005-08-02 2006-07-27 Pdt treatment method for cellulite and cosmetic use
JP2008525043A JP2009503074A (en) 2005-08-02 2006-07-27 Photodynamic therapy and beauty regimen for cellulite
MX2008001547A MX2008001547A (en) 2005-08-02 2006-07-27 Pdt treatment method for cellulites and cosmetic use.
PCT/US2006/029284 WO2007016287A2 (en) 2005-08-02 2006-07-27 Pdt treatment method for cellulites and cosmetic use
RU2008108009/14A RU2444385C2 (en) 2005-08-02 2006-07-27 Method for photodynamic therapy both for treating cellulites, and for cosmetic purposes
IL189019A IL189019A (en) 2005-08-02 2008-01-24 Cosmetic method for reducing cellulite in selective areas in a person and a photosensitizing mixture for treating cellulite tissue
US12/899,003 US8414880B2 (en) 2005-08-02 2010-10-06 PDT treatment method for cellulites and cosmetic use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/899,003 Continuation US8414880B2 (en) 2005-08-02 2010-10-06 PDT treatment method for cellulites and cosmetic use
US12/899,003 Continuation-In-Part US8414880B2 (en) 2005-08-02 2010-10-06 PDT treatment method for cellulites and cosmetic use

Publications (1)

Publication Number Publication Date
US20070031482A1 true US20070031482A1 (en) 2007-02-08

Family

ID=37709188

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/489,873 Abandoned US20070031482A1 (en) 2005-08-02 2006-07-20 PDT treatment method for cellulites and cosmetic use
US12/899,003 Expired - Fee Related US8414880B2 (en) 2005-08-02 2010-10-06 PDT treatment method for cellulites and cosmetic use

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/899,003 Expired - Fee Related US8414880B2 (en) 2005-08-02 2010-10-06 PDT treatment method for cellulites and cosmetic use

Country Status (13)

Country Link
US (2) US20070031482A1 (en)
EP (1) EP1928466B1 (en)
JP (1) JP2009503074A (en)
KR (1) KR101330120B1 (en)
CN (1) CN101568344B (en)
AU (1) AU2006275721B2 (en)
BR (1) BRPI0614453A2 (en)
CA (1) CA2616461C (en)
ES (1) ES2659917T3 (en)
IL (1) IL189019A (en)
MX (1) MX2008001547A (en)
RU (1) RU2444385C2 (en)
WO (1) WO2007016287A2 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014627A1 (en) * 2005-12-02 2008-01-17 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
WO2008088810A2 (en) * 2007-01-18 2008-07-24 Ceramoptec Industries Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
US20080195036A1 (en) * 2005-12-02 2008-08-14 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200863A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200864A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080197517A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080214460A1 (en) * 2007-01-18 2008-09-04 Ceramoptec Industries, Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
US20080248554A1 (en) * 2005-12-02 2008-10-09 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US7967763B2 (en) 2005-09-07 2011-06-28 Cabochon Aesthetics, Inc. Method for treating subcutaneous tissues
US8439940B2 (en) 2010-12-22 2013-05-14 Cabochon Aesthetics, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US8753339B2 (en) 2005-09-07 2014-06-17 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9272124B2 (en) 2005-12-02 2016-03-01 Ulthera, Inc. Systems and devices for selective cell lysis and methods of using same
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US9486274B2 (en) 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050171B2 (en) * 2010-10-04 2015-06-09 William J. Foster Small diameter fragmatome for minimally traumatic retained lens fragments removal
ES2647895T3 (en) * 2012-09-07 2017-12-27 Shiseido Company Ltd. Method for evaluating cellulite and method for evaluating the efficacy of a drug against cellulite using fibulin-3 and / or gamma as an indicator sarcoglycan
JP5899391B1 (en) * 2013-03-22 2016-04-06 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. Skin Treatment apparatus
WO2015069629A1 (en) * 2013-11-06 2015-05-14 Terry Ward Cellulite and fat reducing device and method utilizing optical emitters
RU2565373C9 (en) * 2014-05-20 2016-09-20 Медицинский Центр Высоких Технологий "Лазервита" Method for face and neck skin structure recovery
RU2576788C1 (en) * 2015-04-07 2016-03-10 Екатерина Евгеньевна Фаустова Method of complex restoration and maintenance of the skin, subcutaneous fat, muscle and connective tissue in cosmetology (optional)
CZ307681B6 (en) 2016-02-29 2019-02-13 Ústav makromolekulární chemie AV ČR, v. v. i. A photoactivatable nanoparticle for photodynamic applications, the method of its preparation, a pharmaceutical composition comprising it and their use

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5743215A (en) * 1996-09-30 1998-04-28 Zeff; Jack D. Cat toy for reliably triggering play or attack behavior
US5807385A (en) * 1993-08-02 1998-09-15 Keller; Gregory S. Method of laser cosmetic surgery
US6074666A (en) * 1992-02-05 2000-06-13 Qlt Phototherapeutics, Inc. Liposome compositions of porphyrin photosensitizers
US6206873B1 (en) * 1996-02-13 2001-03-27 El. En. S.P.A. Device and method for eliminating adipose layers by means of laser energy
US20010056294A1 (en) * 2000-05-19 2001-12-27 Ushio Denki Kabushiki Kaisya Discharge lamp for photodynamic therapy and photodynamic diagnosis
US6605080B1 (en) * 1998-03-27 2003-08-12 The General Hospital Corporation Method and apparatus for the selective targeting of lipid-rich tissues
US20050215524A1 (en) * 2004-02-12 2005-09-29 Ceramoptec Industries, Inc. Methods and compositions for improving photodynamic therapy through administration of lipids
US20060035952A1 (en) * 2004-08-16 2006-02-16 Ceramoptec Industries, Inc. Photosensitizer formulations and their use
US7354599B2 (en) * 2003-08-26 2008-04-08 Ceramoptec Industries, Inc. Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454842B (en) * 1984-11-01 1988-06-06 Pharmacia Ab Composition for priority over the ophthalmological applications containing a check vattenlosning hogmolekyler of a polymer and a dissolved polymeric fergemne
US5484778C1 (en) * 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
US5587396A (en) * 1994-08-26 1996-12-24 Mary Kay Inc. Method of ameliorating cellulite by disrupting the barrier function of the stratum corneum
DE4440337A1 (en) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmaceutical nanosuspensions for drug administration than systems with increased saturation solubility and dissolution rate
IT1279011B1 (en) * 1995-06-15 1997-12-02 Ips Int Prod Services Apparatus for the detection and selection of treatments of cellulite
IL114459D0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Method for detecting and/or monitoring the effectiveness of treatment of T cell mediated diseases
US6120987A (en) * 1997-12-12 2000-09-19 Cis Bio International Non-aggregated fluorescent conjugates and the process for their preparation
FR2767704A1 (en) * 1997-09-04 1999-03-05 Medlight Sa A light diffuser for the photodynamic treatment of organs
EP0911023A1 (en) * 1998-03-20 1999-04-28 Antonio Casale Pharmaceutical or cosmetic compositions containing photosensitizing substances
US20020004053A1 (en) * 1998-08-25 2002-01-10 Biel Merrill A. Cellular or acellular organism eradication via photodynamic activation of a cellular or acellular organism specific immunological response
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6936044B2 (en) * 1998-11-30 2005-08-30 Light Bioscience, Llc Method and apparatus for the stimulation of hair growth
JP2002200181A (en) * 2000-10-31 2002-07-16 Shigehiro Kubota Laser treatment instrument
DE10107575A1 (en) * 2001-02-06 2002-08-08 Beate Roeder Non-invasive reduction of adipose tissue, useful for therapeutic or cosmetic application, uses the photodynamic effect to kill fat cells
US6743215B2 (en) 2001-04-06 2004-06-01 Mattioli Engineering Ltd. Method and apparatus for skin absorption enhancement and cellulite reduction
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US20040232169A1 (en) * 2003-05-23 2004-11-25 Alberto-Culver Company Dispenser and related dispensing method
JP2005008565A (en) * 2003-06-19 2005-01-13 Naris Cosmetics Co Ltd Body-slenderizing cosmetic
CA2529953A1 (en) * 2003-06-23 2004-12-29 Transpharma Medical Ltd. Transdermal delivery system for cosmetic agents
US7754798B2 (en) * 2003-08-28 2010-07-13 Cryovac, Inc. Oxygen scavenger block copolymers and compositions
US20050085455A1 (en) * 2003-10-16 2005-04-21 Light Sciences Corporation Photodynamic therapy for local adipocyte reduction
US7416519B2 (en) * 2004-07-20 2008-08-26 Heck Robert W Massage and resistance training apparatus and method
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
FR2941151B1 (en) * 2009-01-22 2012-05-11 Caster Lentinus extract for its action on cellulite and fat deposits.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US6074666A (en) * 1992-02-05 2000-06-13 Qlt Phototherapeutics, Inc. Liposome compositions of porphyrin photosensitizers
US5807385A (en) * 1993-08-02 1998-09-15 Keller; Gregory S. Method of laser cosmetic surgery
US6206873B1 (en) * 1996-02-13 2001-03-27 El. En. S.P.A. Device and method for eliminating adipose layers by means of laser energy
US5743215A (en) * 1996-09-30 1998-04-28 Zeff; Jack D. Cat toy for reliably triggering play or attack behavior
US6605080B1 (en) * 1998-03-27 2003-08-12 The General Hospital Corporation Method and apparatus for the selective targeting of lipid-rich tissues
US20010056294A1 (en) * 2000-05-19 2001-12-27 Ushio Denki Kabushiki Kaisya Discharge lamp for photodynamic therapy and photodynamic diagnosis
US7354599B2 (en) * 2003-08-26 2008-04-08 Ceramoptec Industries, Inc. Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy
US20050215524A1 (en) * 2004-02-12 2005-09-29 Ceramoptec Industries, Inc. Methods and compositions for improving photodynamic therapy through administration of lipids
US20060035952A1 (en) * 2004-08-16 2006-02-16 Ceramoptec Industries, Inc. Photosensitizer formulations and their use

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7967763B2 (en) 2005-09-07 2011-06-28 Cabochon Aesthetics, Inc. Method for treating subcutaneous tissues
US9005229B2 (en) 2005-09-07 2015-04-14 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9358033B2 (en) 2005-09-07 2016-06-07 Ulthera, Inc. Fluid-jet dissection system and method for reducing the appearance of cellulite
US9364246B2 (en) 2005-09-07 2016-06-14 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US9486274B2 (en) 2005-09-07 2016-11-08 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US8753339B2 (en) 2005-09-07 2014-06-17 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US8366643B2 (en) 2005-09-07 2013-02-05 Cabochon Aesthetics, Inc. System and method for treating subcutaneous tissues
US9011473B2 (en) 2005-09-07 2015-04-21 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US20080200863A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US9272124B2 (en) 2005-12-02 2016-03-01 Ulthera, Inc. Systems and devices for selective cell lysis and methods of using same
US20080014627A1 (en) * 2005-12-02 2008-01-17 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080248554A1 (en) * 2005-12-02 2008-10-09 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080195036A1 (en) * 2005-12-02 2008-08-14 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US9248317B2 (en) 2005-12-02 2016-02-02 Ulthera, Inc. Devices and methods for selectively lysing cells
US20080197517A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US20080200864A1 (en) * 2005-12-02 2008-08-21 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
WO2008088810A3 (en) * 2007-01-18 2008-12-18 Ceramoptec Ind Inc Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
US20080214460A1 (en) * 2007-01-18 2008-09-04 Ceramoptec Industries, Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
US20110021973A1 (en) * 2007-01-18 2011-01-27 Ceramoptec Industries, Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
WO2008088810A2 (en) * 2007-01-18 2008-07-24 Ceramoptec Industries Inc. Formulations for cosmetic and wound care treatments with photosensitizers as fluorescent markers
WO2009005995A1 (en) * 2007-06-29 2009-01-08 Cabochon Aesthetics, Inc. Devices and methods for selectively lysing cells
US10220122B2 (en) 2007-10-09 2019-03-05 Ulthera, Inc. System for tissue dissection and aspiration
US9039722B2 (en) 2007-10-09 2015-05-26 Ulthera, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite
US8906054B2 (en) 2009-08-07 2014-12-09 Ulthera, Inc. Apparatus for reducing the appearance of cellulite
US9044259B2 (en) 2009-08-07 2015-06-02 Ulthera, Inc. Methods for dissection of subcutaneous tissue
US9078688B2 (en) 2009-08-07 2015-07-14 Ulthera, Inc. Handpiece for use in tissue dissection
US8979881B2 (en) 2009-08-07 2015-03-17 Ulthera, Inc. Methods and handpiece for use in tissue dissection
US8920452B2 (en) 2009-08-07 2014-12-30 Ulthera, Inc. Methods of tissue release to reduce the appearance of cellulite
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US8900261B2 (en) 2009-08-07 2014-12-02 Ulthera, Inc. Tissue treatment system for reducing the appearance of cellulite
US8900262B2 (en) 2009-08-07 2014-12-02 Ulthera, Inc. Device for dissection of subcutaneous tissue
US8894678B2 (en) 2009-08-07 2014-11-25 Ulthera, Inc. Cellulite treatment methods
US9510849B2 (en) 2009-08-07 2016-12-06 Ulthera, Inc. Devices and methods for performing subcutaneous surgery
US9757145B2 (en) 2009-08-07 2017-09-12 Ulthera, Inc. Dissection handpiece and method for reducing the appearance of cellulite
US10271866B2 (en) 2009-08-07 2019-04-30 Ulthera, Inc. Modular systems for treating tissue
US8439940B2 (en) 2010-12-22 2013-05-14 Cabochon Aesthetics, Inc. Dissection handpiece with aspiration means for reducing the appearance of cellulite

Also Published As

Publication number Publication date
JP2009503074A (en) 2009-01-29
EP1928466B1 (en) 2017-11-22
CA2616461C (en) 2013-10-01
IL189019A (en) 2013-10-31
WO2007016287A2 (en) 2007-02-08
RU2008108009A (en) 2009-09-10
ES2659917T3 (en) 2018-03-20
AU2006275721B2 (en) 2012-11-29
EP1928466A4 (en) 2012-12-19
IL189019D0 (en) 2008-08-07
CN101568344B (en) 2014-06-11
AU2006275721A1 (en) 2007-02-08
RU2444385C2 (en) 2012-03-10
CN101568344A (en) 2009-10-28
US20110152745A1 (en) 2011-06-23
MX2008001547A (en) 2008-09-11
BRPI0614453A2 (en) 2012-12-11
WO2007016287A9 (en) 2008-10-30
US8414880B2 (en) 2013-04-09
EP1928466A2 (en) 2008-06-11
WO2007016287A3 (en) 2008-12-18
CA2616461A1 (en) 2007-02-08
KR20080039968A (en) 2008-05-07
KR101330120B1 (en) 2013-11-15

Similar Documents

Publication Publication Date Title
Fritsch et al. Photodynamic therapy in dermatology
Szeimiesa et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study
Cairnduff et al. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer
Nelson et al. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine
Choudhary et al. Photodynamic therapy in dermatology: a review
Zeitouni et al. Photodynamic therapy for nonmelanoma skin cancers: current review and update
US6600951B1 (en) Targeting of sebaceous follicles as a Treatment of sebaceous gland disorders
KR101173716B1 (en) Apparatus for treatment of dermatological conditions
JP4659980B2 (en) Carbon dioxide-containing viscous composition
AU2003220671B2 (en) Low intensity light therapy for the manipulation of fibroblast-derived mammalian cells and collagen
Weiss et al. Early clinical results with a multiple synchronized pulse 1064 nm laser for leg telangiectasias and reticular veins
US6235016B1 (en) Method of reducing sebum production by application of pulsed light
Marmur et al. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer
Gold et al. The use of photodynamic therapy in dermatology: results of a consensus conference
Kennedy et al. Photodynamic therapy with endogenous protoporphyrin: IX: basic principles and present clinical experience
Kozarev et al. Novel laser therapy in treatment of onychomycosis
Ericson et al. Review of photodynamic therapy in actinic keratosis and basal cell carcinoma
Kübler et al. Treatment of oral leukoplakia by topical application of 5-aminolevulinic acid
KR101835047B1 (en) Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin
US5658323A (en) Method and apparatus for dermatology treatment
Gold et al. 5‐aminolevulinic acid photodynamic therapy: where we have been and where we are going
Calzavara-Pinton Repetitive photodynamic therapy with topical δ-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours
Kübler et al. Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck
RU2170574C2 (en) Method and composition for regenerating skin looking old
Gerritsen et al. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy

Legal Events

Date Code Title Description
AS Assignment

Owner name: CERAMOPTEC INDUSTRIES, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CASTRO, DANILO;NEWBERGER, WOLFGANG;REEL/FRAME:018221/0535

Effective date: 20060712

AS Assignment

Owner name: CERAMOPTEC INDUSTRIES, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CASTRO, DANILO;NEUBERGER, WOLFGANG;REEL/FRAME:018250/0619;SIGNING DATES FROM 20060712 TO 20060824

AS Assignment

Owner name: BIOLITEC PHARMA MARKETING LTD., MALAYSIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOLITEC, INC.;REEL/FRAME:022482/0944

Effective date: 20090331

Owner name: BIOLITEC PHARMA MARKETING LTD.,MALAYSIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOLITEC, INC.;REEL/FRAME:022482/0944

Effective date: 20090331

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION